Medulloblastoma (MB) comprises clinically and molecularly distinct tumors that arise either in the cerebellum or brainstem [1] [2] [3] . Although current treatments improve survival rates, patients suffer severe side effects and relapse of tumors carrying resistance mutations, underscoring an urgent need for alternative targeted therapies. Deregulation of G protein−coupled receptor (GPCR) pathways has been implicated in medulloblastoma [4] [5] [6] ; however, the underlying signal transduction events that drive tumor initiation and progression remain obscure. GNAS encodes the heterotrimeric Gs protein α subunit (Gα s ), which functions as a molecular switch to transmit various GPCR signals to control cell growth, survival and motility 7 . Recent genome-wide analyses of somatic mutations in cancers identified GNAS as one of the most frequently mutated genes 8 . Although most somatic tumor types acquire gain-of-function GNAS mutations 8 , our analysis of a copy number database (Tumorscape, Broad Institute) unexpectedly revealed that MB displays a marked loss of the chromosomal region containing GNAS (Supplementary Fig. 1 ) compared to other cancers. Furthermore, a recent case report showed that a 14-month-old infant with a previously unknown homozygous nonsense mutation within the GNAS coding region developed MB 9 . Herein, we tested whether deregulation of Gα s -coding GNAS may contribute to MB formation.
Medulloblastoma (MB) comprises clinically and molecularly distinct tumors that arise either in the cerebellum or brainstem [1] [2] [3] . Although current treatments improve survival rates, patients suffer severe side effects and relapse of tumors carrying resistance mutations, underscoring an urgent need for alternative targeted therapies. Deregulation of G protein−coupled receptor (GPCR) pathways has been implicated in medulloblastoma [4] [5] [6] ; however, the underlying signal transduction events that drive tumor initiation and progression remain obscure. GNAS encodes the heterotrimeric Gs protein α subunit (Gα s ), which functions as a molecular switch to transmit various GPCR signals to control cell growth, survival and motility 7 . Recent genome-wide analyses of somatic mutations in cancers identified GNAS as one of the most frequently mutated genes 8 . Although most somatic tumor types acquire gain-of-function GNAS mutations 8 , our analysis of a copy number database (Tumorscape, Broad Institute) unexpectedly revealed that MB displays a marked loss of the chromosomal region containing GNAS (Supplementary Fig. 1 ) compared to other cancers. Furthermore, a recent case report showed that a 14-month-old infant with a previously unknown homozygous nonsense mutation within the GNAS coding region developed MB 9 . Herein, we tested whether deregulation of Gα s -coding GNAS may contribute to MB formation.
RESULTS

GNAS defines a subset of aggressive SHH-group tumors
Human MB can be classified into at least four principal subgroups, WNT (Wingless) group, SHH group, group 3 and group 4, on the basis of their distinct gene expression profiles 1 . To determine the correlation of GNAS in MB subgroups, we examined GNAS expression from two independent, nonoverlapping patient cohorts in Boston and Heidelberg [10] [11] [12] . We found that low GNAS expression tightly correlated with significantly decreased overall survival within SHH-group tumors (SHH-MB), which comprise approximately 30% of all MBs 1 (Fig. 1a,b) . Notably, we did not observe the prognostic impact of low GNAS expression in other group tumors and across MB subgroups (Fig. 1c,d and Supplementary Figs. 2 and 3 ). These observations 1 0 3 6 VOLUME 20 | NUMBER 9 | SEPTEMBER 2014 nature medicine suggest that low expression or loss of GNAS specifically defines a subset of aggressive SHH-group MBs.
Loss of Gnas in neural progenitors induces MB formation
To determine whether Gnas inactivation could lead to brain tumorigenesis, we deleted Gnas in neural stem/progenitor cells by breeding mice with floxed Gnas (Gnas fl/fl ) with a human GFAP promoter−driven Cre (hGFAP-Cre) mouse line 13, 14 . Strikingly, all resulting hGFAP-Cre−hemizygous Gnas fl/fl conditional-knockout mice (designated as GFAP-Gnas mice) developed MB-like tumors at adult stages ( Fig. 2a,b) . We observed expansion of granule neuron progenitors (GNPs) in the cerebellar external granular layer (EGL) beginning at neonatal stages, when the control cerebellum contained only a few rows of GNPs on its surface. Diffuse, continuous GNP expansion continued to increase at postnatal stages. GFAP-Gnas cerebella were exophytic and delineated by a thick and disorganized EGL (Fig. 2a) . By six weeks, GFAP-Gnas mice developed a diffuse MB-like tumor exhibiting the densely packed, small, round, blue GNP-like histology ( Fig. 2c) , resembling the histological features of human MB 15 . In the mutants at postnatal day 60 (P60), the neoplastic cells were highly proliferative, as indicated by extensive expression of Ki67, 10, 11 were divided into two groups using the median GNAS expression value as the cutoff point. The relationship between GNAS mRNA expression and survival time was analyzed according to the Kaplan-Meier method, using log-rank statistics. GNAS levels and patient numbers: a, low (n = 16), high (n = 17); b, low (n = 10), high (n = 10); c, low (n = 32), high (n = 32); d, low (n = 64), high (n = 65). which was barely detectable in Gnas fl/+ control mice (Fig. 2d) . 100% of GFAP-Gnas animals succumbed to their tumor around 3−4 months of age (Fig. 2e) . Although the hGFAP-Cre−recombined cells appear in most brain regions 13 , tumor formation was confined to the cerebellum during the lifespan of GFAP-Gnas mice.
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To ascertain gene expression alterations caused by Gnas loss, we examined mRNAs isolated from the cerebella of control and GFAPGnas mice at P60 by RNA deep sequencing. In tumors of GFAP-Gnas mice, our data revealed an upregulation of Shh signaling pathway components (Fig. 2f) . Quantitative RT-PCR confirmed that expression of Shh target genes and pathway components was significantly upregulated (Fig. 2g) . Consistent with this finding, mRNA in situ hybridization revealed intense expression of Shh-downstream genes including Gli1, Gli2, Ptch1 and Ccnd1 (encoding Cyclin D1) (Fig. 2h) . Furthermore, we observed significant elevation of Shh direct target genes Gli1 and Ptch1 (Fig. 2i) in GNP-like tumor cells compared with normal GNPs, suggesting a cell-intrinsic effect of Gnas mutation on Shh signaling activation. By contrast, expression of Wnt-target genes was not substantially altered ( Supplementary Fig. 4) , which is consistent with previous findings that Gnas loss does not affect Wnt signaling in other cellular systems 16 . We observed widespread expression of the GNP markers Zic1 and Atoh1 (also known as Math1), along with Shh-regulated targets, including Olig2 (ref. 17) , but very few astrocytic GFAP + astrocytes (Fig. 2j) . Thus, Gnas loss results in an increase or, alternatively, a derepression of physiological levels of Shh pathway activity and over-proliferation of GNP-like tumor cells.
Ga s activity and cAMP suppress hedgehog signaling and MB growth To test whether the GTPase activity of Gα s protein is required for inhibition of Shh signaling, we treated GNP cells isolated from wildtype neonates with NF449, a selective Gα s antagonist 18 , which prevents GTP binding to Gα s and blocks Gα s GTPase activity. Treatment with NF449 resulted in a significant upregulation of the Shh target genes Gli1, Gli2, Ptch1 and Mycn and caused a decrease of intracellular cAMP levels (Fig. 3a) , suggesting that inhibition of Gα s GTPase activity activates Shh signaling. To investigate the effect of Gα s gainof-function activity on Shh signaling, we generated a constitutively activated form of Gα s , Gα s Q227L (GsCA), which resulted in an active GTPase-defective, GTP-bound Gα s protein 19 . Overexpression of GsCA in GNPs suppressed the upregulation of Gli1, Ptch1, Mycn and Ccnd1 induced by the Shh agonist (SAG) (Fig. 3b) , indicating that Gα s activation inhibits hedgehog signaling.
The classic signal transduction pathway of Gα s is through activation of adenylyl cyclase, which, in turn, produces intracellular cAMP 20 . cAMP has been shown to activate cAMP-dependent protein kinase A (PKA), a negative effector of Shh signaling [21] [22] [23] . Tumor cells isolated from GFAP-Gnas mice had a significant reduction in intracellular cAMP levels, whereas treatment of tumor cells with the adenylyl cyclase agonist forskolin (FSK) elevated cAMP levels ( Fig. 3c) . To test the hypothesis that cAMP elevation could inhibit Shh signaling activation, we treated GFAP-Gnas GNPs with rolipram, which elevates cAMP levels by selectively inhibiting phosphodiesterase-4 activity to block cAMP degradation 24, 25 , FSK or a nonhydrolyzable cAMP analog, db-cAMP. Each of these cAMP-raising agents significantly reduced expression of Gli1 and Ptch1 (Fig. 3d) . In addition, in wild-type GNPs, treatment with FSK or rolipram enhanced the proteolytic processing of full-length Gli3 into a repressive form, Gli3R (Fig. 3d) , an inhibitor of Shh target expression 26, 27 . In contrast, inhibition of cAMP-dependent PKA with two different small-molecule inhibitors, H89 and KT570, significantly increased expression of Gli1, Ptch1 and Ccnd1 (Fig. 3e) . Furthermore, inhibition of PKA activity by H89 ( Supplementary Fig. 5 ) could restore Shh target expression suppressed by constitutively activated Gα s (Fig. 3f) . Thus, our data are in keeping with previous observations that Gα s -mediated signaling can elevate cAMP levels to inhibit hedgehog target gene expression through cAMP-dependent PKA activity in other cellular systems 26, 28, 29 .
To determine the effects of cAMP elevation on tumor growth in vivo, we evaluated the efficacy of rolipram, which is well tolerated and readily crosses the blood-brain barrier in vivo 24, 30 . Wild-type control and GFAP-Gnas mice at the young-adult stage, P35, were randomized to receive either vehicle or rolipram intraperitoneally daily for 30 d at a dosage exhibiting effective anti-tumor activity in vivo 30 and assessed for tumor development. Rolipram administration during this period did not affect overall cerebellar structure and myelin formation ( Fig. 3g and Supplementary Fig. 6 ). Vehicle-treated GFAP-Gnas mice displayed extensive tumor cell expansion and bulged cerebella (Fig. 3g) . In contrast, in rolipram-treated GFAP-Gnas mice, the tumor size and proliferation of Zic1 + GNP-like tumor cells were substantially reduced (Fig. 3g-i) . In addition, rolipram treatment resulted in a significantly extended lifespan of GFAP-Gnas mice (Fig. 3j) . Thus, elevation of the Gα s effector cAMP by rolipram could lead to inhibition of tumor growth in GFAP-Gnas mice. 
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Ga s controls ciliary trafficking of Shh signaling components Ciliary trafficking of signaling components has an important role in regulating Shh pathway activity and MB formation 22, 31, 32 . Notably, we observed that Gα s was highly enriched at the primary cilium of GNPs (Fig. 4a) but hardly detectable in mouse embryonic fibroblasts (Supplementary Fig. 7) , suggesting a unique ciliary function of Gα s for GNP development. In the presence of Shh, ciliary localization of Gα s was diminished (Fig. 4a,b) . Treatment of GNPs with Shh or its agonist SAG 33 did not alter the total amount of Gα s protein in cells but rather reduced the overall amount of the GTP-bound, active form of Gα s protein (Gα s -GTP; Supplementary Fig. 8 ).
In GNPs from GFAP-Gnas mice, Gα s expression was essentially depleted, whereas total levels of Smoothened (Smo) protein were comparable to those in control GNPs (Supplementary Fig. 9 ). At the tips of cilia, approximately 64.3 ± 6.2% cells exhibited strong immunoreactivity for Gli2, a Shh downstream effector (Fig. 4c) , whereas Gli2 was hardly detectable or weakly present in wild-type control GNPs (Fig. 4c,d ). Consistent with a principal function of PKA in restraining Gli2 activation 21, 23 , our observation suggests that Gnas loss reduces cAMP-dependent PKA activity and increases Gli2 accumulation at ciliary tips, leading to Shh signaling activation. We further detected ciliary translocation of the Smo seven-transmembrane-domain protein in the majority of GFAP-Gnas GNPs, but not in control GNPs, where Smo was diffusely localized in the cytoplasm near the base of cilia but absent from ciliary shafts (Fig. 4e,g ). Conversely, a Smo-inhibiting protein, Ptch1, was mainly detected in the ciliary shaft of control GNPs (Fig. 4f) but absent from cilia in GFAP-Gnas mice (Fig. 4f,g ). In contrast, ciliary trafficking of a Shh signaling regulator, Gpr161 (ref. 29) , was not altered in GFAP-Gnas mice (Supplementary Fig. 10) , suggesting a specificity of Gα s in regulating ciliary localization of GPCRs. Consistent with the existence of multiple Gα s -mediated GPCRs, Gpr161 −/− embryos exhibited milder developmental defects than Gnas −/− embryos 28 . Given that PKA null mutation has been shown to lead to Gli2 accumulation at the tips of cilia but not to ciliary trafficking of Smo in mouse neural progenitors 21 , our observations of both a strong Gli2 signal at the ciliary tip and Smo ciliary translocation in GFAP-Gnas mice suggest that Gα s might have an additional role in regulating Smo trafficking in primary cilia independent of cAMPdependent PKA activity.
cAMP augments Smo inhibition to suppress GNP proliferation
Our data indicate that Gα s suppresses Shh signaling not only by stimulating intracellular cAMP levels to activate PKA but also perhaps independently by inhibiting Smo translocation. Treatment of GFAPGnas GNPs with GDC-0449, which blocks Smo activation induced by SAG (Supplementary Fig. 11 ) 34 , led to a reduction in Gli1 and Ptch1 expression (Fig. 4h) . Combined treatment with GDC-0449 and rolipram, however, resulted in further inhibition of GFAP-Gnas GNP proliferation than either drug alone (Fig. 4h) .
As GFAP-Gnas GNPs are highly proliferative (Fig. 4i) , we then determined whether cell proliferation is responsive to cAMP elevation and Smo inhibition. The proliferation rate was modestly reduced in GFAP-Gnas GNPs treated with rolipram or GDC-0449, and rolipram exhibited a relatively stronger effect than GDC-0449 (Fig. 4i,j) . However, combinatorial treatment with both drugs caused a greater inhibition of GFAP-Gnas GNP proliferation than either drug alone (Fig. 4i,j) .
Gnas loss in distinct progenitors leads to MB formation SHH-driven MBs may arise from multiple cellular origins in human patients 3 . hGFAP-Cre-mediated Gnas deletion might affect multiple progenitor populations in the posterior fossa. To examine whether Gnas loss in committed GNPs could result in MB formation, we crossed Gnas-floxed mice with an Atoh1-Cre line, which directs Cre expression in GNPs of the cerebellum and dorsal brainstem cochlear nuclei 3, 35 . The resulting Atoh1-Cre-hemizygous Gnas fl/fl (Atoh1-Gnas) mice developed MB-like tumors with an expansion of tumor cells in the EGL (Fig. 5a) . Tumor cells expressed the neuronal markers Tuj1 and Zic1 extensively, with few Olig2-and GFAP-expressing glial cells (Fig. 5b) , and exhibited a significant upregulation of the Shh signaling target genes Ptch1, Gli1 and Hhip (Fig. 5c) . This suggests that ablation of Gnas selectively in committed cerebellar GNPs is sufficient to cause Shh-associated MB formation. To test whether other Shh-responsive progenitor cells were susceptible to oncogenic transformation due to Gnas loss, we ablated Gnas in progenitors expressing the Shh-regulated gene Olig1 (refs. 36,37). During embryogenesis, Olig1 is mainly expressed in the specified progenitors of the brainstem around rhombomeres r2-r4, which can give rise to oligodendrocyte precursors and granule neuron lineage cells 37, 38 (Fig. 5d) . We detected Olig1 + progenitors mainly in the rostral brainstem but separated from caudal brainstem progenitors in rhombomeres r6-r8, a source of Wnt-associated MBs 39 (Fig. 5d) . They were essentially undetectable in the upper rhombic lip (URL), EGL and cochlear nucleus ( Fig. 5d and Supplementary Fig. 12) , the other sources for Shh-associated MBs 3, 35 . Lineage tracing analysis indicated that the progeny of Olig1 + progenitors were present in a population of Zic1 + GNPs in the dorsal brainstem (Fig. 5e) . Notably, Olig1-Cre-heterozygous Gnas fl/fl mice (designated as Olig1-Gnas mice), generated by breeding Gnas-floxed and Olig1-Cre mice, developed anatomically distinct tumors that were largely restricted between the caudal posterolateral lobe and the dorsal brainstem around the fourth ventricle (Fig. 5f) and contiguous within the rostral brainstem (Fig. 5g) . Olig1-Gnas mice developed relatively intact cerebellar structure and morphology, displaying tumor formation around 3 months of age. Approximately 37.4 ± 4.1% of cells in the tumor tissues expressed Ki-67 (Fig. 5h) , suggesting that the neoplastic cells are highly proliferative. In tumors of Olig1-Gnas mice, we detected extensive expression of the neuronal markers NeuN, Zic1 and Pax6 (Fig. 5i) , a hallmark feature of a primitive neuroectodermal tumorlike MB 40 . In contrast, only a few scattered cells in the tumor were positive for the astrocytic marker GFAP (Fig. 5j) .
Anatomically distinct Gnas-mutant tumors resemble SHH-MB
Although the localization of MBs is distinct between Olig1-Gnas and GFAP-Gnas mice (Fig. 1) , transcriptome profiling by RNA-seq (Fig. 6a) and quantitative RT-PCR (qRT-PCR) (Fig. 6b) analysis revealed a substantial upregulation of Shh pathway components in tumors of either origin. Regression analysis revealed a direct correlation of gene transcription profiles between GFAP-Gnas and Olig1-Gnas tumors (Fig. 6c) . Cross-species comparison of gene expression profiles of Gnas tumors with data from human MB subgroups using two different class prediction algorithms, agreement of differential expression (AGDEX) 41 (Fig. 6d,e) and prediction analysis of DKK2  EMX2  GAD1  TNC  WIF1  ATOH1  EYA1  HHIP  PDLIM3  SFRP1  EGFL11  GABRA5  IMPG2  MAB21L2  NPR3  NRL  EOMES  KCNA1  KHDRBS2  OAS1  RBM24 npg microarrays (PAM) 42 (Fig. 6f) , revealed that the tumors derived from both GFAP-Gnas and Olig1-Gnas mice showed a gene expression signature most closely resembling the SHH-group human MB (Fig. 6d-f) . Therefore, our data highlight Olig1 + progenitors in the mouse posterior fossa as a key source of a subset of Shh-associated tumors, consistent with their heterogeneous cellular origins 3 .
To further examine the tumorigenic capacity of neoplastic cells in these Gnas-mutant mice, we transplanted cells isolated from tumor tissues from GFAP-Gnas or Olig1-Gnas mice by stereotactically injecting them into the forebrain of immunocompromised nude mice. Tumor cells were able to propagate in the brain of the transplanted animals, and tumors became obvious upon visual inspection 1 month after transplantation (Supplementary Fig. 13 ). Tumors formed in mouse allografts comprised GNP-like tumor cells exhibiting MB histology (Supplementary Fig. 13 ). Congruent with gene profiling and histological data, this suggests that the tumors in GFAP-Gnas or Olig1-Gnas mice consist of neoplastic cells, resembling SHH-MBs. Moreover, to identify the subgroup affiliation of MB in the patient with a homozygous GNAS-inactivating mutation 9 , we carried out targeted gene-expression profiling analysis and observed a significant upregulation of SHH-group signature genes but not of WNT-group, group-3 or group-4 MB genes (Fig. 6g) . Thus, our results predict that the tumor carrying the GNAS nonsense mutation is an SHH-MB with high confidence (Fig. 6g) . Furthermore, a recent genome sequencing study identified 8 cases out of 133 SHH-MBs carrying GNAS mutations, including one case with a frameshift mutation 5 Table 1 ). These studies suggest that GNAS-inactivating mutations may lead to SHH-MB formation in patients.
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DISCUSSION
We demonstrate here that the Gnas-encoded GPCR signal transducer Gα s is a potent tumor suppressor in Shh-MBs. Gnas expression determines progenitor cell competency in initiation of MBs among distinct cells of origin in mice. In humans, we found that low levels of GNAS define a subset of aggressive SHH-MB, suggesting that GNAS should be tested as a prognostic biomarker for treatment stratification of SHH-associated tumors. The case report that a patient with a homozygous GNAS nonsense mutation 9 developed SHH-MB provides additional clinical relevance of GNAS deregulation in tumor formation. Our gain-and loss-of-function studies suggest that Gα s inhibits MB formation at least in part by suppressing Shh signaling through activating the cAMP-dependent pathway to regulate Gli3 processing and Gli2 activation, as well as modulating ciliary trafficking of hedgehog signaling components in GNPs. Thus, a dual-mode regulation of the intracellular cAMP signaling cascade and Smo activation at the primary cilium by Gα s reinforces the inhibition of Shh signaling and blocks MB initiation. Our data further suggest that Gα s might serve as a point of convergence between Smo and various Gα s -coupled GPCR signaling pathways 4, 6, 29, 43 to modulate Shh signal strength and control MB formation. We did not detect significant alterations of gene loci encoding hedgehog-pathway components, including PTCH1, SMO and SUFU, in GNAS-low SHH-MBs 44 or in Gnas tumors ( Supplementary Fig. 14 and Supplementary Table 1) , suggesting that MBs with GNAS deregulation or inactivation may represent a unique subset of SHH-MBs. Nonetheless, our copy number variation study revealed that a number of other genetic alterations occurred in both GFAP-Gnas and Olig1-Gnas mice. The altered genetic loci harboring homozygous deletions included Tulp4, a candidate tumor suppressor gene in MB 39 , and Hjurp, a critical factor for chromosome segregation and stability 45, 46 (Supplementary Fig. 14) . These genetic alterations might potentially contribute to transforming mechanisms in Gnas mutants.
We identify Olig1 + progenitors as a cellular source for Shh-associated tumors in mice localized to the dorsal brainstem, demonstrating the cellular and anatomic heterogeneity within SHH-MB 2, 3, 5, 47 . As recent studies indicate that Olig1 may be an arbiter of the oligodendrocyte precursor and cerebellar interneuron fate decision 48 , it is possible that interneuron precursors might contribute to MB formation. However, this seems unlikely because Shh-driven MBs are derived from lineage-restricted GNPs even with SmoM2 activation or Ptch1 mutation in cerebellar stem/progenitor cells 13, 35 .
The ventral brainstem of GFAP-Gnas mice exhibits an expanded pontine gray nucleus derived from lower rhombic lip progenitors, which could also act as a source of Wnt-subgroup tumor 39 . Thus, Gα s may suppress MB formation in different types of progenitor cells. Together, our studies uncover Gα s as a potential molecular link among anatomically distinct MBs, pointing to a previously unrecognized tumor suppressor function of Gnas in the initiation of diverse MBs, in contrast to other tumor types caused by activating GNAS mutations 8, 49 .
Although Smo inhibitors efficiently suppress MB growth in animal models such as Ptch1 loss-of-function mutant mice 50 and in adult humans with SHH-MB 51 , in these studies the drug responses were only transient owing to the emergence of drug resistance. Our data suggest that cAMP stimulants such as rolipram, which possesses antitumor activity and is clinically approved already as an antidepressant in humans in Japan and Europe 52 , might be a potent alternative agent against aggressive SHH-MBs caused by GNAS inactivation. Although other cAMP-raising agents have been previously proposed for the treatment of human tumors exhibiting overactive SHH pathways 52 , our current model of spontaneous MB in GFAP-Gnas mice gives evidence for the efficacy of rolipram in vivo, for which anti-tumor effects had remained unexplored. This suggests that rolipram and perhaps other cAMP-raising agents, including bioflavonoids, which overcome multidrug resistance in cancer therapy 53, 54 , might be repurposed for treating MB. The specific impact of Gα s on MB tumorigenesis suggests a new alternative treatment avenue, such that co-targeting of Gα s or its signaling effectors together with Smo inhibition might circumvent the drug resistance seen with Smo antagonists alone 51, 55 and could be beneficial in treatment of aggressive SHH-MB with GNAS deregulation.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The RNA-seq, mRNA Affymetrix GeneChip microarray and aCGH microarray data are deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE53248. RNA-seq data analysis. We isolated RNAs from the cerebella of adult wild-type mice and tumor tissue from individual GFAP-Gnas or Olig1-Gnas mutants and subject it to RNA deep sequencing. RNA-seq libraries were prepared using the Illumina RNA-seq Preparation Kit (Illumina) and sequenced in the HiSeq 2000 sequencer. RNA-seq reads were mapped using TopHat with default settings. TopHat output data was then analyzed by Cufflinks to calculate FPKM values for known transcripts in mouse genome reference and test for changes of gene expression of control and tumor tissues.
Copy number variation analysis. We isolated genomic DNAs from the cerebellum of adult wild-type mice and tumor tissue from individual GFAP-Gnas or Olig1-Gnas mutants (n = 3 for each genotype) using a DNA preparation kit (Zymo Inc.) and hybridized them on aCGH arrays (Nimblegen, Mouse CGH 3x720K Whole-Genome Tiling Array) according to the manufacturer's protocol. Data from the aCGH arrays were analyzed using the Nexus aCGH software with recommended normalization settings. Each sample was compared to a distributed baseline to identify amplified and deleted regions using a segmentation algorithm within Nexus Suite using a cutoff with gain (≥ 0.23) and loss (≤ −0.5) and significance threshold = 1.0 × 10 −5 . Segments showing copy number variation were only reported if they occurred in list those regions of gain or loss with an individual False Discovery Rate (FDR) no greater than 5%.
Classification of medulloblastoma patient subgroups. Classification of a group of 103 paraffin-embedded MB samples was established using unsupervised hierarchical clustering (HCL) as the training series described previously 57, 58 . Unsupervised HCL of MB expression data identified the following four unique sample clusters: WNT-group, SHH-group, group-3 and group-4. Briefly, gene expression data from MB samples were generated by using Affymetrix_HTHG-U133A chips (Affymetrix, Santa Clara, CA). Molecular subgroups were classified using TM4 Microarray Software Suite (MeV v4.4; Dana-Farber Cancer Institute, Boston, MA). Subgroup-specific signature genes were identified by a multivariate permutation test. We performed principal component analysis (PCA) of gene expression data using Partek Genomics Suite (Partek, St. Louis, MO).
Subgroup determination of the tumor with a homozygous GNAS nonsense mutation from a 14-month-old post-mortem infant. Total RNA was extracted from FFPE tumor tissue using the Qiagen RNeasy FFPE Kit (Qiagen, Hilden, Germany), and 200 ng of total RNA were analyzed on a nanoString nCounter using a custom 25-gene probe set as previously described 58 . Counts were normalized to the three housekeeping genes (GAPDH, ACTB and LDHA), and subgroup prediction was done using PAM (prediction analysis of microarrays), as previously described using the R-statistical environment (v2.15.1) 58 .
Molecular classification of mouse tumors.
Mouse tumors and normal cerebella (n = 8 each group) were profiled on the Affymetrix GeneChip Mouse Gene 1.1 ST v1 platform. Transcript-level Robust Multi-array Average (RMA) normalization was performed using the oligo package (v 1.14) 59 in the R environment (v 2.15). Mouse transcripts were mapped to human transcripts using gene orthology predicted by EnsemblCompara GeneTrees 60 available on Ensembl BioMart (GRCm38 data set). Subsequently, the expression profiles were analyzed to assign molecular MB subgroup to the mouse tumors, using the AGDEX R package (v 1.0.1) 41 and human MB expression data from Northcott et al. 57 . In this cross-species comparison of global differential expression, mouse normal cerebellum and human normal cerebellum were used as references. The degrees of agreement in differential expression of the mouse tumors between each of the four human MB subgroups were assessed separately and tested for statistical significance using permutation tests.
The molecular classification of the mouse tumors was also performed using a class prediction algorithm, Prediction Analysis for Microarrays (PAM) 42 , as implemented in the pamr package (v 1.51). The mouse and human samples first were normalized to their respective cerebellar references. Subgroup-specific markers were identified based on Kruskal-Wallis tests with multiple hypothesis correction by the Benjamin-Hochberg method, using a false discovery rate threshold of 0.01 and a signal-to-noise ratio threshold of 1.5. The resulting 545 subgroup-specific signature markers were used as features for class prediction of the mouse tumors using a PAM classifier trained on the human MB samples. Predicted subgroups with confidence probabilities higher than established thresholds 58 were considered bona fide subgroup assignments. Plots were generated by Principal Component Analyses (PCA) on the expression profiles of human medulloblastomas (training data). The resulting eigen vectors were used to project the expression profiles of the classified samples onto the vector space spanned by the first two eigen vectors of the training data. The background confidence score gradient was generated using 200 replicates of the training data with added Gaussian noise and subsequently smoothed by Nadaraya-Watson normalization (fields v6.7.6 R package).
Rolipram treatment in mice and volumetric measurement of tumors. Control and GFAP-Gnas mutant mice at P30-P35 were randomized to receive either eolipram (5 mg kg −1 ) or vehicle control (5% (v/v) DMSO) administered twice daily via intraperitoneal injection as previously described 30 . Brain tissues were harvested and processed into 8-µm sections in the sagittal plane and stained with hematoxylin and eosin (H/E) or subject to immunostaining. Abnormal tissue area with densely packed cells and round-to-oval hyperchromatic nuclei was assumed to be tumor tissue in the tissue section. For volumetric measurement, sections of cerebella were scanned by using a ScanScope XT from Aperio (Vista, CA) to acquire serial section images, then stacked and aligned with the StackReg function of ImageJ to generate three-dimension models and analyzed with Imaris Software (Bitplane) to calculate the volume of tumor tissues.
Intracranial transplantation. Tumor cells isolated from Gα s mutants were plated in GNP culture medium and harvested with 0.25% trypsin and 0.02% EDTA for 2 min, washed twice with Hank's balanced salt solution (HBSS), and resuspended in Ca 2+ and Mg 2+ -free HBSS. Cell viability was determined by trypan blue exclusion. Only single-cell suspensions with more than 90% viability were used for in vivo allograft studies. Cells (5 × 10 5 ) were stereotactically injected into the lateral ventricle of nude mice (6-week-old BALB/c nu/nu; -coordinates: anterior-posterior, +1.8; medial-lateral, +2.2; dorsal-ventral, -2.0 mm from Bregma).
Statistical analyses. All analyses were done using Microsoft Excel or Prism GraphPad 6.00 for Mac OS (San Diego, CA, http://www.graphpad.com). Quantifications were performed from at least three independent experimental groups. Data are presented as mean ± s.e.m. in the graphs. P values are from Student's two-tailed t-test to compare two sets of data. To compare more than two sets, we used one-way analysis of variance analysis (ANOVA) with a Newman-Keuls multiple comparison test for post hoc analysis. Survival analyses used animal death times and censoring times when animals were sacrificed or as otherwise stated. Survival curves were plotted with the Kaplan-Meier method and compared by using a two-sided log-rank test. In human tumor data analysis, Fisher's exact test was used for data in Tumorscape database unless otherwise specified. P < 0.05 is considered to be statistically significant.
